Patients harboring mutations in theligand-binding domain of PPARγ have a stereotyped phenotype characterized bypartial lipodystrophy, severe insulin resistance, dyslipidemia, hepaticsteatosis, and hypertension, thus identifying PPARγ as playing a molecular role in thepathogenesis of the metabolic syndrome [43, 44]. The gene discussed is PPARG; the disease is Hypertension.